DOP2011000067A - Derivados de picolinamida como inhibidores de cinasa - Google Patents

Derivados de picolinamida como inhibidores de cinasa

Info

Publication number
DOP2011000067A
DOP2011000067A DO2011000067A DO2011000067A DOP2011000067A DO P2011000067 A DOP2011000067 A DO P2011000067A DO 2011000067 A DO2011000067 A DO 2011000067A DO 2011000067 A DO2011000067 A DO 2011000067A DO P2011000067 A DOP2011000067 A DO P2011000067A
Authority
DO
Dominican Republic
Prior art keywords
compositions
kinase
compounds
formula
new compounds
Prior art date
Application number
DO2011000067A
Other languages
English (en)
Inventor
Matthew T Burger
Wooseok Han
Jiong Lang
Gisele Nishiguchi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000067(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2011000067A publication Critical patent/DOP2011000067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan nuevos compuestos de fórmula II: y composiciones. En ciertas modalidades, los compuestos y composiciones cumplen la función de ser efectivos en la inhibición de la actividad de cuando menos una cinasa Maloney de integración del provirus (Cinasa PIM) asociada con tumorgénesis. Los nuevos compuestos de fórmula II y composiciones se pueden utilizar ya sea solos o bien en combinación con cuando menos un agente adicional para el tratamiento de un trastorno mediado por una cinasa de serina/treonina o por un receptor de cinasa de tirosina, tal como cáncer incluyendo malignidades hematopoyéticas, carcinomas, melanoma, trastornos mieloides, adenomas, sarcomas, enfermedades autoinmunes, reacciones alérgicas, y en los síndromes de rechazo de trasplantes de órganos. Un ejemplo de los compuestos de picolinamida desarrollados es el siguiente:
DO2011000067A 2008-09-02 2011-03-02 Derivados de picolinamida como inhibidores de cinasa DOP2011000067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9366608P 2008-09-02 2008-09-02
US22566009P 2009-07-15 2009-07-15

Publications (1)

Publication Number Publication Date
DOP2011000067A true DOP2011000067A (es) 2017-01-15

Family

ID=41228825

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000067A DOP2011000067A (es) 2008-09-02 2011-03-02 Derivados de picolinamida como inhibidores de cinasa

Country Status (38)

Country Link
US (4) US8329732B2 (es)
EP (1) EP2344474B1 (es)
JP (2) JP5412519B2 (es)
KR (1) KR101345920B1 (es)
CN (3) CN104311480A (es)
AU (1) AU2009289319C1 (es)
BR (1) BRPI0918268B1 (es)
CA (1) CA2734415C (es)
CL (1) CL2011000454A1 (es)
CO (1) CO6351725A2 (es)
CR (1) CR20110114A (es)
DK (1) DK2344474T3 (es)
DO (1) DOP2011000067A (es)
EA (1) EA020136B1 (es)
EC (1) ECSP11010859A (es)
ES (1) ES2551900T3 (es)
GE (1) GEP20135849B (es)
HN (1) HN2011000629A (es)
HR (1) HRP20151410T1 (es)
HU (1) HUE026381T2 (es)
IL (1) IL211291A (es)
MA (1) MA32684B1 (es)
ME (1) ME01291A (es)
MX (1) MX2011002365A (es)
MY (1) MY150136A (es)
NI (1) NI201100052A (es)
NZ (1) NZ591449A (es)
PE (1) PE20110298A1 (es)
PL (1) PL2344474T3 (es)
PT (1) PT2344474E (es)
RS (1) RS54506B1 (es)
SI (1) SI2344474T1 (es)
SM (1) SMT201600005B (es)
SV (1) SV2011003849A (es)
TW (1) TWI434843B (es)
UY (1) UY32085A (es)
WO (1) WO2010026124A1 (es)
ZA (1) ZA201101118B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
JP5564045B2 (ja) * 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA201290957A1 (ru) * 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
JP2013530199A (ja) * 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2675816A4 (en) * 2011-02-14 2014-08-13 Univ Alberta BORIC ACID CATALYSTS AND USE METHOD FOR THE ACTIVATION AND TRANSFORMATION OF CARBOXYLIC ACIDS
JP2014506915A (ja) * 2011-03-04 2014-03-20 ノバルティス アーゲー キナーゼ阻害剤としての四置換シクロヘキシル化合物
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PE20150194A1 (es) * 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
EP2943485B1 (en) * 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
US9113629B2 (en) * 2013-03-15 2015-08-25 Dow Agrosciences Llc 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN105611928A (zh) * 2013-08-08 2016-05-25 诺华股份有限公司 Pim激酶抑制剂组合
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
MX2016006894A (es) * 2013-11-27 2016-08-17 Novartis Ag Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN106573927B (zh) 2014-03-18 2019-09-27 豪夫迈·罗氏有限公司 氧杂环庚烷-2-基-吡唑-4-基-杂环基-甲酰胺化合物和使用方法
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105130959B (zh) * 2015-09-18 2018-08-03 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN107522695B (zh) * 2016-06-21 2018-09-14 上海方予健康医药科技有限公司 一种pim激酶抑制剂的盐酸盐及其制备方法和用途
CN107522696B (zh) * 2016-06-21 2019-02-19 上海方予健康医药科技有限公司 一种嘧啶类化合物的盐酸盐及其制备方法和用途
CN112043712B (zh) * 2016-06-21 2022-04-29 上海方予健康医药科技有限公司 嘧啶化合物的盐酸盐在制备用于治疗与flt3相关的疾病或障碍的药物中的应用
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11236048B2 (en) * 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN110078706B (zh) * 2019-05-31 2022-02-01 浙江师范大学 一种伊马替尼衍生物及其制备方法和用途
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
JP7657792B2 (ja) 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
PT4077307T (pt) 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ，インク． スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112915086B (zh) * 2021-01-27 2022-04-12 广州市力鑫药业有限公司 一种含有Akt靶向激酶抑制剂的药物组合物
IL305952A (en) 2021-03-19 2023-11-01 Crinetics Pharmaceuticals Inc Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
US20240327355A1 (en) * 2021-07-21 2024-10-03 Chugai Seiyaku Kabushiki Kaisha Method for producing arylamide derivative
JP2026509318A (ja) 2022-10-31 2026-03-18 スミトモ・ファーマ・アメリカ・インコーポレイテッド 骨髄増殖性新生物を治療するためのｐｉｍ１阻害剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251134A4 (en) 2000-01-26 2003-01-29 Meiji Seika Kaisha NEW CARBAPENEM DERIVATIVES OF THE QUATERNARY SALT TYPE
AU2001231143A1 (en) * 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
HRPK20050957B3 (en) * 2005-11-11 2008-09-30 Džanko Nikša Collapsible hanger
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
MX2009004786A (es) * 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
ES2431163T3 (es) * 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
WO2009014637A2 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체
UY31679A1 (es) * 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
WO2010026124A1 (en) * 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
US8809380B2 (en) 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
EP2665711A1 (en) 2011-01-21 2013-11-27 Abbvie Inc. Picolinamide inhibitors of kinases

Also Published As

Publication number Publication date
US8329732B2 (en) 2012-12-11
US20100056576A1 (en) 2010-03-04
GEP20135849B (en) 2013-06-10
EA201100425A1 (ru) 2011-10-31
HN2011000629A (es) 2015-08-10
CN103333157A (zh) 2013-10-02
NZ591449A (en) 2012-12-21
TWI434843B (zh) 2014-04-21
CO6351725A2 (es) 2011-12-20
IL211291A (en) 2014-05-28
US20150315150A1 (en) 2015-11-05
AU2009289319B2 (en) 2011-10-27
CN104311480A (zh) 2015-01-28
DK2344474T3 (en) 2015-12-14
US20140079693A1 (en) 2014-03-20
CR20110114A (es) 2011-05-10
PL2344474T3 (pl) 2016-03-31
CA2734415A1 (en) 2010-03-11
MY150136A (en) 2013-11-29
MX2011002365A (es) 2011-04-04
UY32085A (es) 2010-03-26
NI201100052A (es) 2011-09-03
WO2010026124A1 (en) 2010-03-11
EA020136B1 (ru) 2014-08-29
TW201028393A (en) 2010-08-01
KR101345920B1 (ko) 2014-02-06
BRPI0918268B1 (pt) 2021-08-03
AU2009289319C1 (en) 2013-12-05
SV2011003849A (es) 2011-07-07
HUE026381T2 (en) 2016-06-28
HK1156627A1 (en) 2012-06-15
AU2009289319A1 (en) 2010-03-11
SMT201600005B (it) 2016-02-25
EP2344474A1 (en) 2011-07-20
BRPI0918268A2 (pt) 2020-11-17
ES2551900T3 (es) 2015-11-24
JP5813701B2 (ja) 2015-11-17
CL2011000454A1 (es) 2011-09-30
CN102203079A (zh) 2011-09-28
JP2013231049A (ja) 2013-11-14
EP2344474B1 (en) 2015-09-23
HK1162022A1 (en) 2012-08-17
PE20110298A1 (es) 2011-05-21
RS54506B1 (sr) 2016-06-30
JP2012501314A (ja) 2012-01-19
PT2344474E (pt) 2015-12-28
SI2344474T1 (sl) 2015-12-31
IL211291A0 (en) 2011-04-28
MA32684B1 (fr) 2011-10-02
ME01291A (me) 2013-06-20
KR20110048585A (ko) 2011-05-11
ECSP11010859A (es) 2011-04-29
JP5412519B2 (ja) 2014-02-12
US20120134987A1 (en) 2012-05-31
HRP20151410T1 (hr) 2016-01-15
ZA201101118B (en) 2011-09-28
CA2734415C (en) 2016-07-26
CN102203079B (zh) 2014-12-10
US9079889B2 (en) 2015-07-14
US8592455B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
ECSP11010859A (es) Derivados de picolinamida como inhibidores de cinasa
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
ECSP24009853A (es) Compuestos tricíclicos como inhibidores de kras
CL2012000324A1 (es) Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CU23784B7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
NI201000156A (es) Compuestos heterocíclicos novedosos y usos de los mismos.
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
CL2009001058A1 (es) Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
CL2019000986A1 (es) 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds).
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
EA201290305A1 (ru) Производные трициклического пиразоламина
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
PE20171738A1 (es) Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos
MA33059B1 (fr) Utilisation d'antagonistes des recepteurs nk
MX2024002110A (es) Derivados fenil y piridopirazol como inhibidores del receptor con dominio discoidina 1 (ddr1).
ATE548364T1 (de) Aminopyrazolkinasehemmer
MX2009013667A (es) Inhibidores triciclicos de hidroxiesteroide deshidrogenasas.
CL2011001850A1 (es) Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.
MD3996C2 (ro) Percloraţi de 5-R-saliciliden-4-feniltiosemicarbazonato(1-)-aquacupru(II) ce posedă proprietăţi de inhibitori ai activităţii enzimei 17 b-HSD (tipul 1)